Conference Interview #3 of 12
Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)
Liz Meszaros, MDLinx
Iselin, New Jersey, United States | November 13-14, 2017
The partnership was launched in July 2016 to address and fill the gaps in antibiotic research, development, and innovation in improving the diagnosis and treatment of drug-resistant infections. John H. Rex, MD, FACP, chief medical officer, F2G Ltd., Manchester, UK, explains the inception of CARB-X, its goals, and achievements.
From this Conference
-
1:38Role of physicians in antimicrobial resistanceIselin, NJ, November 14, 2017—William Weiss, PhD, director, UNT Health Science Center, Fort Worth, TX, discusses the key role physicians can play in slowing down...
William Weiss, PhD -
0:47Antibiotic use in livestock drives resistance in humansIselin, NJ, November 13, 2017--Antibiotic resistance in animals contributes to antibiotic resistance in humans through several avenues, and is one of the primary factors...
John H. Rex, MD, FACP -
1:34Antibiotic resistance: Exploring the broken pipelineIselin, NJ, November 13, 2017--For the past few years, experts have acknowledged that the antibiotic pipeline is broken.
John H. Rex, MD, FACP -
4:27Indwelling medical devices cause the majority of hospital-acquired infectionsIselin, NJ, November 14, 2017--About 70% of all hospital-acquired infections are due to the use of indwelling medical devices, and roughly 5% to 10% of hospitalized...
Carl Genberg, BSc, JD, CEO -
1:26A full course of antibiotics: Do the benefits outweigh the risksIselin, NJ, November 14, 2017—William Weiss, PhD, director, UNT Health Science Center, Fort Worth, TX, shares insight into how physicians can influence antimicrobial...
William Weiss, PhD -
3:39Antibiotic resistance: The fate of all antibiotic monotherapiesIselin, NJ, November 13, 2017--Is antibiotic resistance the fate of all antibiotic monotherapies?
John H. Rex, MD, FACP
This activity is neither sanctioned by, nor a part of the SMi group's annual meeting.
